Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) will report fourth quarter and full year 2025 financial and business results after market close on February 24, 2026. Management will host a conference call and webcast the same day at 4:30 p.m. ET.
The event will include prepared remarks, a Q&A session, and a live webcast available on the company Investor Relations website; a replay will be accessible for 60 days following the call.
Positive
- None.
Negative
- None.
News Market Reaction – SUPN
In the Feb 13 session, SUPN gained 1.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Regulatory approval | Positive | -3.7% | Health Canada authorized ZURZUVAE for adults with postpartum depression. |
| Dec 03 | Conference participation | Neutral | +0.2% | Management presented at the Bank of America 2025 CNS Therapeutics Virtual Conference. |
| Nov 21 | Conference participation | Neutral | -0.4% | CEO joined a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. |
| Nov 12 | Conference participation | Neutral | -0.4% | CEO participated in the 2025 Jefferies Global Healthcare Conference in London. |
| Nov 04 | Quarterly earnings | Positive | +2.3% | Q3 2025 revenue rose to $192.1M with guidance raised after Sage acquisition. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent SUPN news has mostly seen modest, aligned price moves, with one notable divergence where positive regulatory news on ZURZUVAE coincided with a share price decline.
Over the last several months, Supernus has combined steady investor outreach with meaningful business developments. Q3 2025 results showed total revenue of $192.1M, 9% growth year over year, supported by Qelbree, GOCOVRI, and ONAPGO, and the completion of the Sage acquisition on July 31, 2025. Subsequent 8-Ks highlighted ONAPGO supply constraints from strong demand and the timing of earnings releases. Health Canada’s authorization of ZURZUVAE for postpartum depression added a regulatory milestone. Today’s earnings date announcement fits this pattern of regular financial communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2025 financial and business results on Tuesday, February 24, 2026, at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
